ArticleBMJ open gastroenterology2026
Proton-pump inhibitor exposure and prevalence of colorectal adenoma: a retrospective analysis from the Sakkopi study.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProton-pump inhibitors (PPIs) are among the most widely prescribed long-term medications worldwide, yet concerns remain about their potential role in colorectal carcinogenesis. Experimental data suggest that PPI-induced hypergastrinaemia may promote colonic epithelial proliferation, but epidemiological findings are inconsistent, and colonoscopy-based evidence is limited.
methodsWe studied 4476 asymptomatic adults who underwent structured screening colonoscopy in Austria between 2007 and 2020 as part of the Sakkopi study. Regular PPI use, including dose stratification, was evaluated in this retrospective analysis in relation to adenoma prevalence, burden and anatomical distribution. Multivariable logistic regression was adjusted for age, sex, metabolic syndrome, smoking status and family history of colorectal cancer. Multinomial models examined non-advanced and advanced adenomas separately.
resultsA total of 322 (7.2%) participants reported regular PPI use. Compared with non-users, PPI users were older, had higher body mass index and more frequently fulfilled metabolic syndrome criteria. Adenomas were detected in 39% of PPI users and 33% of non-users (p=0.032). In adjusted analyses, PPI use was not associated with adenoma presence (OR 1.05; 95% CI 0.83 to 1.35), number or distribution. Dose stratification showed no gradient effect: adjusted ORs were 0.85 (0.58 to 1.26) for half-dose and 1.19 (0.83 to 1.7) for standard-dose therapy. Multinomial analyses yielded consistent null results for both non-advanced and advanced adenomas in adjusted analysis.
conclusionIn this large and well-characterised screening cohort, regular PPI therapy was not associated with colorectal adenoma prevalence, irrespective of dose or lesion characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.